Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: Prevalence, biochemical data and treatment

Endocrine Journal

Volumn 62, Issue 9, 2015, Pages 811-816

  Endo, Itsuro ^a   Fukumoto, Seiji ^a   Ozono, Keiichi ^b   Namba, Noriyuki ^b   Inoue, Daisuke ^c   Okazaki, Ryo ^c   Yamauchi, Mika ^d   Sugimoto, Toshitsugu ^d   Minagawa, Masanori ^e   Michigami, Toshimi ^f   Nagai, Masaki ^g   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^d SHIMANE UNIVERSITY   (Japan)

^e CHIBA CHILDREN'S HOSPITAL   (Japan)

^f RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

FGF23; Hypophosphatemia; Osteomalacia; Rickets

Indexed keywords

COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; FIBROBLAST GROWTH FACTOR; PHOSPHORUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATEMIA; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; ONCOGENIC OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PREVALENCE; QUESTIONNAIRE; X LINKED HYPOPHOSPHATEMIC RICKETS; BLOOD; FAMILIAL HYPOPHOSPHATEMIC RICKETS; HEALTH SURVEY; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; HEALTH SURVEYS; HUMANS; HYPOPHOSPHATEMIA; INCIDENCE; INFANT; INFANT, NEWBORN; JAPAN; MALE; MIDDLE AGED; PHOSPHORUS; PREVALENCE; YOUNG ADULT;

EID: 84942935508     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0275     Document Type: Article

References (10)

1. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435.
2. Hori M, Shimizu Y, Fukumoto S (2011) Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152: 4-10.
3. Hashimoto S, Fukutomi K, Nagai M, Nakamura Y, Yanagawa H, et al. (1991) [A method of interval estimation for number of patients in the nationwide epidemiological survey on intractable diseases]. Nihon Koshu Eisei Zasshi 38: 880-883 (In Japanese).
4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.
5. Carpenter TO (1997) New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 44: 443-466.
6. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, et al. (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42: 1235-1239.
7. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, et al. (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91: 2055-2061.
8. Jiang Y, Xia WB, Xing XP, Silva BC, Li M, et al. (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res 27: 1967-1975.
9. Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, et al. (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124: 1587-1597.
10. Sato K, Shiraki M (1998) Saccharated ferric oxideinduced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 45: 431-439.